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BRIEF DEFINITIVE REPORT
        Rheumatoid arthritis (RA) is a chronic infl  am-
matory disease aff  ecting     1% of the global pop-
ulation (  1  ). RA is characterized by infi  ltration 
of synovial joints by immune cells, principally 
macrophages, T cells, plasma cells, and hyper-
plasia of the synovial lining. This eventually re-
sults in the destructive phase of disease causing 
damage to cartilage and bone. It is widely ac-
cepted that cytokines and their receptors play a 
central role in the pathogenesis of RA, thus 
TNF    , IL-1, and IL-6 have been identifi  ed as 
key mediators of the disease (  2  –  4  ). The role 
played by members of the TNF receptor super-
family (TNFRSF) in pathological bone resorp-
tion has also become widely accepted, with 
RANK and RANKL acting as crucial factors in 
diff  erentiation of osteoclasts (  5  ), the primary cell 
type involved in bone degradation. 
  DR3 (TRAMP, LARD, Apo3, Wsl1, and 
TNFRSF25) is a member of the TNFRSF and 
shows closest homology to TNFR1 (  6  ). Like 
TNFR1, DR3 contains four extracellular cys-
teine-rich repeats and is capable of signaling 
both apoptosis via caspase 8 activation and cell 
survival via the activation of NF    B (  7  –  9  ). The 
biological function of DR3 is an area of grow-
ing interest. In the immune system, DR3 has 
been shown to aff  ect negative selection during 
thymocyte development (  10  ) and can modu-
late T cell (  11  –  13  ) and NKT cell function (  14  ). 
It has also been associated with infl  ammatory 
diseases such as irritable bowel disease (  15, 16  ) 
and atherosclerosis (  17  ). Interestingly, DR3, 
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  Rheumatoid arthritis (RA) is a chronic infl  ammatory disease of synovial joints that is asso-
ciated with cartilage and bone destruction. Death Receptor 3 (DR3), a tumor necrosis 
factor (TNF) receptor superfamily member, has recently been associated with the patho-
genesis of RA. We demonstrate that absence of DR3 confers resistance to the development 
of adverse bone pathology in experimental antigen-induced arthritis (AIA). DR3  ko   mice 
exhibited a reduction in all histopathological hallmarks of AIA but, in particular, failed to 
develop subchondral bone erosions and were completely protected from this characteristic 
of AIA. In contrast, TNF-like protein 1A (TL1A), the ligand for DR3, exacerbated disease in 
a dose- and DR3-dependent fashion. Analysis of osteoclast number within AIA joint re-
vealed a reduction in areas susceptible to bone erosion in DR3  ko   mice, whereas in vitro 
osteoclastogenesis assays showed that TL1A could directly promote osteoclastogenesis in 
mouse and man. Treatment with antagonistic anti-TL1A mAb protected animals in a sys-
temic model of RA disease collagen-induced arthritis. We therefore conclude that the 
DR3  –  TL1A pathway regulates joint destruction in two murine models of arthritis and 
represents a potential novel target for therapeutic intervention in infl  ammatory joint 
disease. 
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DR3  ko   compared with DR3  wt   mice (  Fig. 1 F  ). This translated 
into a signifi  cant reduction in the AI (  Fig. 1 G  ). 
  As a second outcome measure of structural damage to the 
joint, we assessed proteoglycan depletion from articular carti-
lage on the femoral head using Safranin O/Fast Green stain-
ing 21 d after arthritis induction. In DR3  wt   mice, cartilage 
was severely depleted, as illustrated by lack of red Safranin O 
staining resulting in an obvious tidemark (  Fig. 1 H  ). DR3  ko   
mice did not display much cartilage depletion (  Fig.1 I  ), re-
taining similar levels of Safranin O staining as nonarthritic 
control left knees (not depicted). Collectively, this data indi-
cate that there is considerable protection against degenerative 
AIA disease pathology in DR3  ko   mice. 
  TL1A exacerbates disease in a DR3-dependent fashion 
  To confi  rm that resistance to AIA was DR3 specifi  c, TL1A 
was injected with mBSA on day 0 of the AIA model at escalating 
along with its only known ligand, TNF-like protein 1A 
(TL1A) (  18  ), has been linked with RA. Duplication of the 
DR3 gene is more prevalent in RA patients compared with 
controls (  19  ), whereas TL1A  +   mononuclear phagocytes have 
been identifi  ed in rheumatoid synovium and soluble TL1A 
has been detected in synovial fl  uid of patients (  20  ). However, 
functional analysis of the in vivo role of the DR3  –  TL1A 
pathway in RA has not yet been reported. 
  To address this, we have generated mice lacking the DR3 
gene (DR3  ko  ) on a C57BL/6 background (  10  ) and used a 
salient model of experimental arthritis to elucidate functional 
aspects of DR3 activity. Antigen-induced arthritis (AIA) is a 
local model of disease which displays many pathological fea-
tures of RA including cellular infi  ltration, synovial hyperpla-
sia, pannus formation, cartilage depletion, and bone destruction 
(  21  ). We show that DR3 is essential for the development of 
adverse joint pathology in AIA and that anti-TL1A treatment 
can protect from the systemic model of disease, collagen-
induced arthritis (CIA). These results imply an important 
in vivo function for DR3 in the pathogenesis of infl  ammatory 
arthritis and provide proof of principle that countering this 
pathway may represent a novel therapy for RA. 
    RESULTS AND DISCUSSION   
  DR3  ko   mice show reduced infl  ammatory response to AIA 
compared with DR3  wt   controls 
  To investigate the in vivo role of DR3 in infl  ammatory ar-
thritis, we induced AIA in DR3  ko   mice and DR3  wt   controls. 
All mice developed an infl  ammatory reaction in response to 
intraarticular injection of methylated BSA, with both DR3  ko   
and DR3  wt   mice exhibiting a similar pattern of joint swell-
ing over a 21-d time course. Comparable knee joint swell-
ing measurements were noted in DR3  ko   and DR3  wt   mice 
at the peak of response, 1 d after mBSA injection. There-
after, swelling resolved in both but faster in the absence of 
DR3 (  Fig. 1 A  ).   
  We next assessed whether more rapid resolution of joint 
swelling was translated to improved pathological outcome in 
DR3  ko   mice. Examination of histopathological severity was 
performed on joint sections taken during the acute infl  amma-
tory phase when TNF    , IL-1    , and IL-6 reach a peak and 
destructive pathology fi  rst becomes detectable (3 d after in-
duction) and when there is maximal evidence of structural 
damage within the joint (21 d after induction) (  21  ). The se-
verity of arthritis (arthritis index [AI]) was quantifi  ed in he-
matoxylin and eosin (H  &  E)  –  stained sections by grading 
parameters as described in Materials and methods. On day 3 
after arthritis induction, DR3  wt   (  Fig. 1 B  ) and DR3  ko   mice 
(  Fig. 1 C  ) did not diff  er histopathologically. By day 21, DR3  wt   
mice had developed arthritis characterized by extensive cellu-
lar infi  ltration, synovial hyperplasia, formation of a thick pan-
nus, and bone erosions (  Fig. 1 D  ). In contrast, DR3  ko   mice 
displayed mild pathological features of arthritis, showing gen-
eral absence of synovial hyperplasia, lack of pannus formation, 
and no evidence of bone erosion (  Fig. 1 E  ). Indeed, all scor-
ing parameters were either absent or signifi  cantly milder in 
    Figure 1.         Protection against AIA in DR3  ko   mice.   (A) Joint swelling after 
intraarticular injection of mBSA. Data are mean   ±   SEM from   n   = 6 DR3  wt  
(     ) or DR3  ko   (    ) mice. Two-way analysis of variance (ANOVA) shows signifi  -
cance at P   <   0.02 (*). One representative experiment of three is shown. 
(B  –  E) Representative images from DR3  wt   (B) and DR3  ko   (C) mice, 3 d after 
arthritis induction, and DR3  wt   (D) and DR3  ko   (E) mice, 21 d after arthritis 
induction. Bars, 200   μ  m. Infl  ammatory tissue (black arrowheads) and erosions 
(blue arrowheads) are shown. (F) Breakdown of each component of the AI. *, 
P   <   0.05; **, P   <   0.01. (G) AI scores from DR3  wt   and  DR3 ko   mice. **, P   <   0.01. 
Lines mark means of graphed points. (H and I) Representative images of 
collagen around knee joints from DR3  wt   (H) and DR3  ko   (I) mice. Sections 
were stained with Safranin O/Fast Green to visualize collagen in red. Tidemark 
of cartilage depletion (arrows) is shown. Bars, 50   μ  m. (J) Estimated cartilage 
depletion from DR3  wt   and  DR3 ko   mice. *, P   <   0.05. Each point in the sum-
mary graphs represents a single 6 DR3  wt   (    ) or DR3  ko   (   )  animal.   JEM VOL. 205, October 27, 2008  2459
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  DR3  ko   mice show normal myeloid infi  ltration within 
joints in AIA 
  Recruitment of mononuclear cells to the subintimal synovial 
lining layer and to periarticular adipose tissue adjacent to the 
meniscus is a process characteristic of the AIA model and RA 
patient joints. Indeed, the degree of macrophage (osteoclast 
precursor) infi  ltration within rheumatoid joint has been cor-
related with severity of structural damage in human disease. 
To assess whether reduction in osteoclast number was caused 
by impaired recruitment of these cells to the joint, we per-
formed immunohistochemical analysis of F4/80 expression 
in sections from DR3  ko   and DR3  wt   mice on days 3 and 21 
after arthritis induction. On day 3, some F4/80 expression 
was detected in the periarticular adipose tissue, which did not 
diff  er signifi  cantly between DR3  wt   and DR3  ko   mice (  Fig. 3, 
G  –  I  ). By day 21, F4/80 staining was markedly increased with 
strong F4/80 expression visualized microscopically in both 
quantities up to 100 ng. DR3  het   mice were chosen as they 
showed intermediate AI scores compared with DR3  wt   mice 
(  Figs. 1 G and 2 A  ).   Consequently, exacerbation or ameliora-
tion of disease after TL1A injection could be quantifi  ed, 
irrespective of the inherent variability in the model. Coad-
ministration of TL1A resulted in signifi  cant dose-dependent 
exacerbation of disease in DR3  het   mice (  Fig. 2 A  ). This was 
strikingly illustrated by the eff  ect on size of bone erosions and 
severity of bone destruction, which increased in a dose-
dependent fashion after TL1A injection (  Fig. 2, B and C  ). 
In contrast, TL1A had no signifi  cant eff  ect on arthritis 
progression in DR3  ko   mice over the concentration range 
studied (  Fig. 2 D  ). Representative images of DR3  ko   mice re-
ceiving 1 and 100 ng TL1A show the continued absence of 
bone erosions (  Fig. 2, E and F  ). TL1A therefore exacerbates 
AIA and, in particular, adverse bone pathology in a DR3-
dependent manner. 
  DR3 expression promotes osteoclastogenesis in AIA 
  Because DR3  ko   mice were protected from the development 
of subchondral bone erosions in AIA, we elected to quantify 
the number of bone-resorbing osteoclasts within the joint at 
two distinct sites of epiphyseal bone. Osteoclasts are clearly 
visualized as large red multinucleated cells with tartrate-resis-
tant acid phosphatase (TRAP). TRAP expression in DR3  wt   
and DR3  ko   mice was comparable in the femoral head (  Fig. 3, 
A  –  C  ) and growth plate (not depicted).   However, in the peri-
osteum at areas adjacent to pannus formation, where focal 
bone erosions could be visualized at high magnifi  cation, 
TRAP staining was signifi  cantly greater in DR3  wt   mice than 
at equivalent areas in DR3  ko   mice (  Fig. 3, D  –  F  ). These data 
implicate a role for DR3 in generation of osteoclasts at sites 
of bone pathology but not in infl  uencing osteoclastogenesis 
in areas away from the pannus. 
    Figure 2.         TL1A promotes adverse bone pathology of AIA in a DR3-
dependent manner.   (A) AI with increasing administration of TL1A in 
DR3  het   mice. Horizontal lines mark means of graphed points. Open 
symbols represent DR3  het   mice;  fi  lled symbols represent DR3  ko   mice. 
(B and C) Representative images from DR3  het   mice with no (B) or 100 ng 
(C) TL1A added. Bone erosions (arrowheads) are shown. (D) AI with 
increasing administration of TL1A to DR3  ko   mice. (E and F) Representative 
images from DR3  ko   mice with 1 (E) or 100 (F) ng TL1A added. Bars, 200 
  μ  m. One-way ANOVA showed signifi  cance of TL1A addition to DR3  het   but 
not DR3  ko   mice. *, P   <   0.05. Each point in the summary graphs represents 
a single animal. One representative experiment of two is shown.     
    Figure 3.         TRAP and F4/80 expression in joints of DR3  wt   and DR3  ko   
mice.   Sections were stained for TRAP or F4/80 as described in Materials 
and methods. Horizontal lines mark means of graphed points. 
(A and B) Representative images of TRAP staining at day 21 after arthritic 
induction from DR3  wt   (A) and DR3  ko   (B) mice. Red TRAP  +   staining  (arrows) 
is shown. (C) Summary of TRAP staining in femoral head at day 21. 
(D and E) Representative images of TRAP staining around areas of bone 
erosion at day 21 after arthritic induction from DR3  wt   mice (D) and 
equivalent areas from DR3  ko   mice (E). Red TRAP  +   staining (arrows) is 
shown;   js  , joint space;   p ,  pannus;   c  , cartilage. (F) DR3  ko   mice show signifi  -
cantly reduced TRAP  +   staining compared with DR3  wt   mice. *, P   <   0.05. 
(G and H) Representative images of F4/80 staining from DR3  wt   (G)  and 
DR3  ko   (H) mice, 3 d after arthritis induction. (I) Summary of day-3 data. 
(J and K) Representative images of F4/80 staining from DR3  wt   (J)  and 
DR3  ko   (K) mice, 21 d after induction of arthritis. F4/80-positive cells 
(arrows) are shown. (L) Summary of day-21 data. Each point in the 
summary graphs represents a single DR3  wt   (    ) or DR3  ko   (   )  animal. 
Bars, 50   μ  m. One representative experiment of two is shown.     2460  DR3  –  TL1A IN INFLAMMATORY ARTHRITIS   | Bull et al. 
  The role of the DR3  –  TL1A axis in driving adverse bone 
pathology in infl  ammatory arthritis 
  Our fi  ndings show that DR3  ko   mice are resistant to the ad-
verse joint pathology that is typical in AIA and are consistent 
with an essential role for the DR3  –  TL1A pathway in devel-
opment of infl  ammatory arthritis. DR3  ko   mice elicited an 
initial infl  ammatory reaction in response to AIA induction, 
such that at day 3 after arthritis induction, there was no dif-
ference in histopathological scoring or level of infl  ammatory 
cell infi  ltrate between control and DR3  ko   mice. Resolution 
of infl  ammation, however, occurred at a faster rate in DR3  ko   
mice, as indicated by reduction in joint swelling over the 
course of the study and reduction in all histopathological pa-
rameters measured at day 21 after arthritic induction. Of par-
ticular note was the absence of bone erosion and marked 
reduction in cell infi  ltrate in DR3  ko   mice in later stages of 
disease. Comparable numbers of infi  ltrating F4/80  +   macro-
phages were present in joints of DR3  wt   and DR3  ko   mice, de-
spite the observed diff  erences in joint pathology. Therefore, 
the mechanisms involved in initiating the infl  ammatory reac-
tion and in recruitment of myeloid cells into the joint appear 
DR3  ko   and DR3  wt   mice. Quantifi  cation of F4/80  +   cells again 
revealed no signifi  cant diff  erence in expression between DR3  wt   
and DR3  ko   mice (  Fig. 3, J  –  L  ). Overall, these data suggest that 
absence of DR3 does not impair recruitment of myeloid cells 
to the joint, nor does it aff  ect overall numbers of basal mature 
osteoclasts in the femoral head. Neither hypothesis can ex-
plain the reduction in osteoclast numbers in areas of bone pa-
thology in DR3  ko   mice. 
  TL1A promotes osteoclastogenesis in vitro in a DR3-
dependent fashion 
  We therefore tested the possibility that TL1A could directly 
promote diff  erentiation of osteoclasts. To achieve this, we 
used an in vitro system of osteoclastogenesis from adherent 
BM-derived cells (BMC). BM macrophages (BMM) from 
DR3  wt   mice were confi  rmed to express DR3 (  Fig. 4 A  ).   BMC 
from DR3  wt   and DR3  ko   mice did not diff  er in their ability to 
generate osteoclasts in the presence of soluble RANK-L and 
M-CSF as measured by the formation of multinucleated TRAP  +   
cells (  Fig. 4 B  ). However, TL1A addition signifi  cantly en-
hanced development of osteoclasts from DR3  wt   but not 
DR3  ko   BMC (  Fig. 4, B  –  D  ). TL1A in the absence of RANK-
L and M-CSF could not generate osteoclasts (  Fig. 4 E  ). The 
functional capacity of in vitro  –  generated osteoclasts to de-
stroy bone was visualized by toluidine blue staining of pits in 
the ivory discs (  Fig. 4 F  ). This data indicates that TL1A is not 
necessary for osteoclastogenesis per se, but promotes it in the 
presence of RANK-L and M-CSF and in a DR3-dependent 
fashion. In support of our murine data and highlighting the 
signifi  cance of these results for humans, TL1A signifi  cantly 
promoted osteoclastogenesis from monocytes derived from 
human peripheral blood (  Fig. 4 G  ). 
  Anti-TL1A neutralizing antibody ameliorates AIA and CIA 
  To test the therapeutic potential of countering the DR3  –  TL1A 
pathway, we generated an antagonistic rat mAb to murine 
TL1A (  Fig. 5, A and B  ) and applied it in AIA and the systemic 
model of disease.   CIA is the industry standard for testing poten-
tial therapeutic agents against RA. A single treatment of anti-
TL1A at the point of arthritic induction in AIA resulted in 
more rapid resolution of swelling that mirrored our observa-
tions in DR3  ko   mice (  Fig. 5 C  ). In CIA, clinical signs of arthritis 
became apparent in control mice on day 25 (  Fig. 5 D  ). Disease 
activity was assessed by assigning scores to each paw according 
to degree of redness, swelling, and joint involvement. Paw 
scores in anti-TL1A  –  treated mice were consistently lower than 
in control IgG2a-treated mice, reaching signifi  cance on days 27 
and 28 (  Fig. 5 E  ). Disease activity in control IgG2a-treated 
mice was characterized by leukocyte infi  ltration of synovial tis-
sues and variable degrees of bone erosion (  Fig. 5 F  ). Specimens 
from anti-TL1A  –  treated mice demonstrated mild changes by 
comparison (  Fig. 5 G  ). The AI in anti-TL1A  –  treated mice was 
signifi   cantly less than in IgG2a-treated controls (  Fig. 5 H  ). 
These data are consistent with the protection against AIA ob-
served in DR3  ko   mice and suggest that countering the DR3  –
  TL1A pathway may be therapeutic against RA in man. 
    Figure 4.         TL1A promotes DR3-dependent in vitro osteoclastogen-
esis.   (A) RT-PCR of DR3 in BMM. In vitro osteoclastogenesis assays were 
performed as described in Materials and methods. Osteoclast numbers 
were estimated by counting multinucleated TRAP  +   cells. (B) Effect of TL1A 
on proportion of osteoclasts generated in presence of RANKL and M-CSF. *, 
P = 0.0003. Each point represents a single ivory disc from experiments on 
DR3  wt   (open symbols) or DR3  ko   (fi  lled symbols) mice. Four discs from four 
mice were counted for each treatment. Lines mark means of graphed 
points. One representative experiment of two is shown. (C  –  E) TRAP stain-
ing of BM cells from DR3  wt   mice on discs with RANK-L + M-CSF and no 
TL1A (C) or 10 ng/ml TL1A (D) and TL1A (E), but no RANKL and M-CSF. 
Bars, 50   μ  m. (F) Toluidine blue staining of ivory discs showing pit-forming 
ability of osteoclasts generated in vitro. Bar, 150   μ  m. (G) Effect of TL1A on 
osteoclastogenesis from adherent human peripheral blood mononuclear 
cells and proportion of osteoclasts in cultures shown with (     ) or without 
(     ) exogenous TL1A added. **, P = 0.0013. One representative experiment 
of two is shown.     JEM VOL. 205, October 27, 2008  2461
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intact in the absence of DR3. Because of this, we chose to 
investigate diff  erentiation of osteoclasts, discovering that os-
teoclast diff  erentiation in vitro and bone erosion in vivo was 
exacerbated by exogenous TL1A in control but not DR3  ko   
mice. These DR3-dependent eff  ects confi  rm that TL1A is a 
specifi  c functional ligand for DR3 and identifi  es the control 
of osteoclasts as a novel function for DR3. The potential of 
countering the DR3  –  TL1A pathway as a therapy was proven 
by amelioration of CIA and AIA using a neutralizing anti-
TL1A mAb. Interestingly, anti-TL1A therapy was not totally 
protective. The possibility remains that there may be second-
ary ligands for DR3 and TL1A as implicated for TL1A by re-
cent data in renal infl  ammation (  22  ), but detailed studies have 
shown no other TNFSF/TNFRSF family members that bind 
murine DR3 or murine TL1A (  18  ), whereas human TL1A 
binds Decoy Receptor 3 (  11  ), a mouse homologue of which 
has not been found. 
  This is the fi  rst paper reporting that signaling through 
DR3 on myeloid cells promotes osteoclastogenesis, although 
it is clear from our data that it is not a prerequisite for, nor can 
it induce, this diff  erentiation in the absence of RANK-L and 
M-CSF. In this respect, it mirrors functions that have been 
reported for TNF     (  23  ). However, a function independent of 
TNF     is suggested by a recent paper showing that macro-
phages produce TL1A independent of TNF activity (  20  ). 
TL1A expression, including release of active soluble forms of 
the protein, can be induced on human monocytes by Fc    R 
stimulation through soluble (  24  ) and insoluble immune com-
plexes purifi  ed from RA synovial fl  uid (  20  ). The majority of 
stromal macrophages in RA synovial tissue express TL1A, and 
in vitro stimulation of monocytes with PEG precipitates from 
RA samples results in production of nanogram quantities of 
soluble TL1A (  20  ). This suggests very high levels in localized 
RA joint akin to the levels we used to exacerbate AIA (  Fig. 2 A  ). 
The implication is that in infl   ammatory arthritis, myeloid 
cells may exhibit a positive feedback loop whereby TL1A is 
triggered through ICs and can drive diff  erentiation of bone-
destroying cells if the right cytokine milieu is provided. In-
triguingly, TL1A also has varied eff  ects on human osteoblast 
cell lines in vitro, inhibiting diff  erentiation and promoting 
quiescence at low densities but inducing death at high den-
sities (  25  ). We therefore propose that the DR3  –  TL1A path-
way may act as a switch that is capable of directly activating 
osteoclast but also inhibiting osteoblast diff  erentiation and, in 
so doing, disregulate the homeostatic balance of degradation 
and formation in normal bone into the detrimental situation 
observed in destructive bone pathologies such as RA. Although 
our in vitro data supports this proposal, some caution is neces-
sary in interpreting the contribution of direct TL1A-driven 
osteoclastogenesis to arthritic bone damage in vivo, as infl  am-
mation and bone erosion cannot be dissociated in AIA or CIA. 
The possibility remains that the resistance of DR3  ko   mice to 
bone erosion is secondary to DR3  –  TL1A-dependent control 
of other parts of the infl  ammatory process. 
  In this respect, our data also show that cartilage depletion is 
signifi  cantly reduced in DR3  ko   mice (  Fig. 1  ). Cartilage depletion 
    Figure 5.         Early therapeutic intervention with anti-TL1A antibody 
arrests development of arthritis.   (A) Binding of rat anti-TL1A mAb (TAN 
2  –  2) to J558L cells transfected with plasmid encoding membrane-bound 
TL1A. Shaded histogram and dotted line represent binding of isotype con-
trol and TAN 2  –  2 to plasmid only transfected cells, respectively. Binding of 
isotype control and TAN 2  –  2 to TL1A-expressing cells is represented by a 
thin and thick line, respectively. (B) Titration of TAN 2  –  2 binding to J558L 
cells expressing membrane-bound TL1A. (C) Time course of swelling in AIA 
after anti-TL1A mAb treatment. Data are mean   ±   SEM from mice treated 
with control IgG2A (     ) or anti-TL1A (     ) mAb. One representative experi-
ment of two is shown. *, P   <   0.02 by two-way ANOVA. CIA was induced as 
described in Materials and methods. All data were derived from six mice 
for each treatment. (D) Arthritis incidence tabulated over 28-d time 
course. (E) Arthritis severity as a mean paw score from day 20 when dos-
ing schedule for anti-TL1A and control IgG2a was started. Data are mean   ±   
SEM. Timing of injections are shown (arrows). (F and G) Representative 
images of H  &  E-stained sections from control IgG2a (F) and anti-TL1A 
(G).   i  , intense synovial infi  ltration;   e  , aggressive bone erosion. Bars, 200   μ  m. 
(H) Analysis of AI of CIA in control IgG2a and anti-TL1A  –  treated mice. 
Dotted horizontal line depicts mean for each group. *, P   <   0.05; **, P = 
0.01; ***, P = 0.006.     2462  DR3  –  TL1A IN INFLAMMATORY ARTHRITIS   | Bull et al. 
expressed TL1A. To generate cells expressing membrane-anchored TL1A, 
PCR fragments encoding the entire coding sequence of mouse TL1A were 
cloned into the mammalian expression vectors pEF1/V5-His A and pcDNA3.1 
(Invitrogen), and plasmids were then transfected into J558L or 293T cells. 
Stable J558L cell lines expressing membrane-anchored TL1A were selected 
in Geneticin (400   μ  g/ml)-containing media. Splenic cDNA or IMAGE clone 
30740802 was used as a template for PCR reactions to generate TL1A-en-
coding DNA fragments. Further selection of neutralizing anti-TL1A mAbs 
was based on the ability to block binding of soluble recombinant TL1A-Fc 
to anti-CD3/CD28  –  stimulated T cells. 
  Anti-TL1A therapy in CIA.     CIA was induced as previously described 
(  31  ). In brief, 2 mg/ml of chicken type II collagen (CII; Sigma-Aldrich) was 
emulsifi  ed with an equal volume of complete Freund  ’  s adjuvant and 100   μ  l 
of collagen/adjuvant mixture injected intradermally into several sites near the 
base of the tail of 7-wk-old male DBA/1J mice. A second identical booster 
was administered to each mouse 21 d after the fi  rst injection. The day of the 
fi  rst immunization was designated as day 0. Mice were randomly assigned to 
one of three treatment groups on day 20. Animals received nine daily 100-  μ  l 
injections containing either 2.5 mg/kg of anti-TL1A or LEAF purifi  ed con-
trol rat IgG2a (Cambridge Biosciences) dissolved in sterile PBS or PBS alone 
administered by the i.p. route from day 20. Thereafter, arthritis incidence 
and severity was assessed daily until termination on day 28 when the disease 
severity limits were attained in IgG2a and PBS controls. The incidence of 
CIA was assessed as the percentage of mice developing arthritis among all 
mice. The severity of arthritis in each paw (paw score) was evaluated by using 
an established in-house scoring system: 0, normal; 1, mild but defi  nite swell-
ing in the ankle or wrist joint or redness and swelling limited to individual 
digits regardless of the number of digits aff  ected; 2, moderate swelling of an-
kle or wrist; 3, severe redness and swelling of the ankle or wrist and proximal 
phalangeal joints; and 4, maximally infl  amed limb with involvement of mul-
tiple joints, no ankylosis. 
  Assessment of arthritis.     Joint swelling was assessed on days 1, 2, 3, 5, 7, 
14, and 21 after arthritis induction by measuring the diff  erence between hind 
right (AIA) and hind left (control) knee joint diameters using an analogue 
micrometer. Animals were killed on day 3 or 21 for assessment of infl  amma-
tory and pathological changes within the joint. Histological assessment was 
performed as previously described (  30  ). All joints were fi  xed in neutral buff  -
ered formal saline and decalcifi  ed with 10% formic acid for 2 wk at 4  °  C be-
fore embedding in paraffi   n wax. Serial sections of 7-  μ  m thickness were taken 
and stained routinely with H  &  E for analysis. Two blinded independent ob-
servers scored the sections for cellular infi  ltration (0  –  5), cellular exudate (0  –  3), 
synovial hyperplasia (0  –  3), and bone erosion (0  –  3), with 0 representing a 
normal joint. The sum of all parameters gave the AI. Sections were addition-
ally stained with Safranin O and Fast Green to assess cartilage depletion. 
  RT-PCR.     BMM were generated as previously described (  32  ). RNA was 
extracted from BMM cultures using RNeasy (QIAGEN) after manufacturer  ’  s 
instructions, whereas cDNA was generated and RT-PCR performed ac-
cording to standard Invitrogen protocols. PCR primers were as follows:     -actin, 
forward 5    -CGGCCAGGTCATCACTATTG-3     and reverse 5    -CTCA  G-
TAACCCGCCTAG-3     giving a 410-bp product; and DR3, forward 
5    -CTAAGGCTTGCACTGCTGTCT-3     and reverse 5    -GAGCATCT-
CATACTGCTGGTC-3     giving a 457-bp product. The PCR consisted of 
33 cycles with a 59  °  C annealing temperature. 
  TRAP staining for osteoclasts.     For TRAP staining, joints were decalci-
fi  ed in EDTA (7%), rehydrated, and incubated with TRAP staining solution 
containing 0.1 M acetate buff  er, 0.5 M sodium tartrate, 10 mg/ml naphthol 
AS-MX phosphate, 100   μ  l Triton X-100, and 0.3 mg/ml Fast Red Violet 
LB salt for 3 h at 37  °  C. Sections were then counterstained with hematoxylin 
before mounting in DPX. Images were captured using a digital camera 
(N457; Olympus), and TRAP-positive cells were analyzed using Photoshop 
CS3. 5 (Adobe). Randomly chosen selected areas were used for analysis. 
is attributed to the eff  ects of matrix metalloproteinases (MMPs), 
levels of which are raised in RA joint. In vitro experiments 
on human cell lines have shown that DR3 activation can in-
duce the production of MMP-1, -9, and -13 in THP-1s (  17  ). 
These MMPs have all been associated with RA joint pathol-
ogy (  26  ). In addition, it is also established that TL1A plays an 
important role in T cell function. TL1A has been shown to 
costimulate IL-2 responsiveness (  11  ) and synergize with the 
TCR and IL-12/IL-18 pathways to induce IFN     release (  15, 
27, 28  ). TL1A also amplifi  es cytokine release by NKT cells 
(  14  ) and T cells (  13  ) and regulates the development of proin-
fl  ammatory Th17 cells (  12, 16  ), which are reported to aid os-
teoclastogenesis in autoimmune arthritis (  29  ). The action of 
TL1A on T cells may also be regulated by diff  erential ex-
pression of splice variants of DR3 (  27  ). The exact role of TL1A 
and DR3 on lymphocytes in infl  ammatory arthritis remains 
to be elucidated, but it is interesting to note that we fi  nd nor-
mal anti-mBSA Ab levels in serum, unchanged T cell prolifer-
ation to mBSA in draining lymph nodes of DR3  ko   mice after 
AIA induction, and normal in vitro generation of Th17 cells 
from DR3  ko   splenocytes (unpublished data). 
  In summary, we have induced infl  ammatory arthritis in 
DR3  ko   mice and found that they exhibit strong resistance to 
the adverse pathology observed in AIA. We show DR3-de-
pendent TL1A-driven exacerbation of bone damage in vivo 
and promotion of osteoclastogenesis in vitro. We also show 
that anti-TL1A therapy ameliorates disease. Our data suggest 
that the DR3  –  TL1A pathway is an important component of 
infl  ammatory responses in joint disease and, as such, identifi  es 
a potential therapeutic target for treatment of diseases like 
RA but with potential impact in other diseases involving dis-
rupted bone physiology. 
  MATERIALS AND METHODS 
  Animals.     The DR3 mouse colony was founded from animals supplied by 
Cancer Research UK, London. All experiments were undertaken in male 
WT (DR3  wt  ), heterozygous (DR3  het  ), and KO (DR3  ko  ) mice, which have 
been described previously (  10  ). DBA/1J mice were acquired from Harlan, 
UK. Animals were used at 6  –  8 wk of age. All procedures were approved by 
the Local Research Ethics Committee and performed in strict accordance 
with Home Offi   ce  –  approved licenses PPL 30/1999 and 30/2361. 
  Induction of murine AIA.     AIA was induced as previously described (  30  ). 
In brief, mice were s.c. immunized on two occasions, 1 wk apart, with 1 mg/ml 
mBSA with an equal volume of CFA. An additional i.p. injection of 100   μ  l 
of heat-inactivated   Bordetella pertussis   toxin was administered with the fi  rst 
immunization. AIA was induced in the hind right knee joint via an intraar-
ticular injection of 10 mg/ml mBSA (6   μ  l), administered 21 d after the initial 
immunization. To assess the eff  ect of TL1A or anti-TL1A administration, 
AIA was induced via mBSA injection in conjunction with 1, 10, or 100 ng 
of soluble TL1A (R  &  D Systems) or 100 ng of anti-TL1A mAb. 
  Generation of a rat anti  –  mouse TL1A monoclonal antibody.     Rats 
were immunized with a soluble recombinant TL1A protein consisting of a 
human IgG1 Fc domain, with an additional hinge-like region at the C ter-
minus, linked to the extracellular domain of mouse TL1A (T77-L252). The 
protein was produced in Chinese hamster ovary cells and was purifi  ed by 
immunoaffi   nity chromatography using an anti  –  human Fc mAb. Anti-TL1A 
mAb was generated by standard hybridoma technology and hybridoma su-
pernatants were screened for binding to recombinant soluble and membrane-JEM VOL. 205, October 27, 2008  2463
BRIEF DEFINITIVE REPORT
       8  .   Screaton  ,   G.R.  ,   X.N.     Xu  ,   A.L.     Olsen  ,   A.E.     Cowper  ,   R.     Tan  ,   A.J.   
  McMichael  , and   J.I.     Bell  .   1997  .   LARD: a new lymphoid-specifi  c death 
domain containing receptor regulated by alternative pre-mRNA splic-
ing.       Proc. Natl. Acad. Sci. USA      .     94  :  4615    –    4619  .    
       9  .   Marsters  ,   S.A.  ,   J.P.     Sheridan  ,   C.J.     Donahue  ,   R.M.     Pitti  ,   C.L.     Gray  ,   A.D.   
  Goddard  ,   K.D.     Bauer  , and   A.     Ashkenazi  .   1996  .   Apo-3, a new member 
of the tumor necrosis factor receptor family, contains a death domain 
and activates apoptosis and NF-kappa B.       Curr. Biol.       6  :  1669    –    1676  .    
        10  .   Wang  ,   E.C.  ,   A.     Thern  ,   A.     Denzel  ,   J.     Kitson  ,   S.N.     Farrow  , and   M.J.   
  Owen  .   2001  .   DR3 regulates negative selection during thymocyte 
development.       Mol. Cell. Biol.       21  :  3451    –    3461  .    
        11  .   Migone  ,   T.S.  ,   J.     Zhang  ,   X.     Luo  ,   L.     Zhuang  ,   C.     Chen  ,   B.     Hu  ,   J.S.   
  Hong  ,   J.W.     Perry  ,   S.F.     Chen  ,   J.X.     Zhou  ,   et al  .   2002  .   TL1A is a TNF-
like ligand for DR3 and TR6/DcR3 and functions as a T cell costimu-
lator.       Immunity      .     16  :  479    –    492  .    
        12  .   Pappu  ,   B.P.  ,   A.     Borodovsky  ,   T.S.     Zheng  ,   X.     Yang  ,   P.     Wu  ,   X.     Dong  , 
  S.     Weng  ,   B.     Browning  ,   M.L.     Scott  ,   L.     Ma  ,   et al  .   2008  .   TL1A-DR3 in-
teraction regulates Th17 cell function and Th17  –  mediated autoimmune 
disease.       J. Exp. Med.       205  :  1049    –    1062  .    
        13  .   Meylan  ,   F.  ,   T.S.     Davidson  ,   E.     Kahle  ,   M.     Kinder  ,   K.     Acharya  ,   D.   
  Jankovic  ,   V.     Bundoc  ,   M.     Hodges  ,   E.M.     Shevach  ,   A.     Keane-Myers  , 
  et al  .   2008  .   The TNF-family receptor DR3 is essential for diverse T cell-
mediated infl  ammatory diseases.       Immunity      .     29  :  79    –    89  .    
        14  .   Fang  ,   L.  ,   B.     Adkins  ,   V.     Deyev  , and   E.R.     Podack  .   2008  .   Essential role 
of TNF receptor superfamily 25 (TNFRSF25) in the development of 
allergic lung infl  ammation.       J. Exp. Med.       205  :  1037    –    1048  .    
        15  .   Bamias  ,   G.  ,   C.     Martin     III  ,   M.     Marini  ,   S.     Hoang  ,   M.     Mishina  ,   W.G.     Ross  , 
  M.A.    Sachedina  ,  C.M.    Friel  ,  J.    Mize  ,  S.J.    Bickston  ,  et al .  2003  .  Expression, 
localization, and functional activity of TL1A, a novel Th1-polarizing cy-
tokine in infl  ammatory bowel disease.       J. Immunol.       171  :  4868    –    4874  .   
        16  .   Takedatsu  ,   H.  ,   K.S.     Michelsen  ,   B.     Wei  ,   C.J.     Landers  ,   L.S.     Thomas  ,   D.   
  Dhall  ,   J.     Braun  , and   S.R.     Targan  .   2008  .   TL1A (TNFSF15) regulates 
the development of chronic colitis by modulating both T-Helper 1 and 
T-Helper 17 activation.       Gastroenterology      .     135  :  552    –    567  .    
        17  .   Kang  ,   Y.J.  ,   W.J.     Kim  ,   H.U.     Bae  ,   D.I.     Kim  ,   Y.B.     Park  ,   J.E.     Park  ,   B.S.   
  Kwon  , and   W.H.     Lee  .   2005  .   Involvement of TL1A and DR3 in induc-
tion of pro-infl  ammatory cytokines and matrix metalloproteinase-9 in 
atherogenesis.       Cytokine      .     29  :  229    –    235  .    
        18  .   Bossen  ,   C.  ,   K.     Ingold  ,   A.     Tardivel  ,   J.L.     Bodmer  ,   O.     Gaide  ,   S.     Hertig  , 
  C.     Ambrose  ,   J.     Tschopp  , and   P.     Schneider  .   2006  .   Interactions of tumor 
necrosis factor (TNF) and TNF receptor family members in the mouse 
and human.       J. Biol. Chem.       281  :  13964    –    13971  .    
        19  .   Osawa  ,   K.  ,   N.     Takami  ,   K.     Shiozawa  ,   A.     Hashiramoto  , and   S.     Shiozawa  . 
  2004  .   Death receptor 3 (DR3) gene duplication in a chromosome re-
gion 1p36.3: gene duplication is more prevalent in rheumatoid arthritis.   
    Genes Immun.       5  :  439    –    443  .    
        20  .   Cassatella  ,   M.A.  ,   G.P.     da Silva  ,   I.     Tinazzi  ,   F.     Facchetti  ,   P.     Scapini  ,   F.   
  Calzetti  ,  N.    Tamassia  ,  P.    Wei  ,  B.    Nardelli  ,  V.    Roschke  ,  et al .  2007  .  Soluble 
TNF-like cytokine (TL1A) production by immune complexes stimulated 
monocytes in rheumatoid arthritis.       J. Immunol.       178  :  7325    –    7333  .   
        21  .   Simon  ,   J.  ,   R.     Surber  ,   G.     Kleinstauber  ,   P.K.     Petrow  ,   S.     Henzgen  ,   R.W.   
  Kinne  , and   R.     Brauer  .   2001  .   Systemic macrophage activation in locally-
induced experimental arthritis.       J. Autoimmun.       17  :  127    –    136  .    
        22  .   Al-Lamki  ,   R.S.  ,   J.     Wang  ,   A.M.     Tolkovsky  ,   J.A.     Bradley  ,   J.L.     Griffi   n  ,   S.   
  Thiru  ,   E.C.     Wang  ,   E.     Bolton  ,   W.     Min  ,   P.     Moore  ,   et al  .   2008  .   TL1A 
both promotes and protects from renal infl  ammation and injury.       J. Am. 
Soc. Nephrol.       19  :  953    –    960  .    
        23  .   Lam  ,   J.  ,   S.     Takeshita  ,   J.E.     Barker  ,   O.     Kanagawa  ,   F.P.     Ross  , and   S.L.   
  Teitelbaum  .   2000  .   TNF-alpha induces osteoclastogenesis by direct 
stimulation of macrophages exposed to permissive levels of RANK 
ligand.       J. Clin. Invest.       106  :  1481    –    1488  .    
        24  .   Prehn  ,   J.L.  ,   L.S.     Thomas  ,   C.J.     Landers  ,   Q.T.     Yu  ,   K.S.     Michelsen  , 
and   S.R.     Targan  .   2007  .   The T cell costimulator TL1A is induced by 
FcgammaR signaling in human monocytes and dendritic cells.       J. Immunol.     
  178  :  4033    –    4038  .   
        25  .   Borysenko  ,   C.W.  ,   V.     Garcia-Palacios  ,   R.D.     Griswold  ,   Y.     Li  ,   A.K.     Iyer  , 
  B.B.     Yaroslavskiy  ,   A.C.     Sharrow  , and   H.C.     Blair  .   2006  .   Death receptor-3 
mediates apoptosis in human osteoblasts under narrowly regulated con-
ditions.       J. Cell. Physiol.       209  :  1021    –    1028  .    
  Immunohistochemistry for F4/80 expression.     F4/80 expression was 
detected using an anti  –  rat HRP-DAB staining kit (R  &  D Systems) according 
to the manufacturer  ’  s instructions. In brief, sections were rehydrated and en-
dogenous peroxidase activity was blocked. Antigen unmasking was achieved 
by incubating the sections in 0.1% prewarmed Trypsin/EDTA in PBS for 
30 min at 37  °  C. After blocking steps, sections were incubated overnight 
with 4   μ  g/ml of rat anti-F4/80 antibody (Invitrogen) or isotype control di-
luted in PBS followed by secondary antibody as per the manufacturer  ’  s in-
structions. Positively labeled cells were visualized using a streptavidin-HRP 
conjugate and DAB chromogen. Sections were counterstained with he-
matoxylin, dehydrated, and mounted in DPX. Images were captured us-
ing a digital camera (N457), and F4/80 positive cells were analyzed using 
Photoshop. Randomly selected areas were used for analysis. 
  In vitro osteoclastogenesis assays.     BMC were removed from femurs of 
DR3  wt   and DR3  ko   mice by centrifugation after removal of the proximal end. 
BMC were resuspended in     -MEM supplemented with 10% FCS, 2 mM   l-
  glutamine, and antibiotics (MEM-10) and 5   ×   10  5   cells added to ivory discs. 
After 2 h at 37    °   C, nonadherent cells were removed by transfer of ivory discs 
to new wells with fresh media supplemented with 50 ng/ml RANKL and 
25 ng/ml M-CSF with or without 10 ng/ml TL1A. All media were replen-
ished after 3 d. TRAP staining was performed according to the manufactur-
er  ’  s instructions (Sigma-Aldrich) after 7 d. Six fi  elds of view on each disc 
were counted for TRAP-positive multinucleated cells. For human osteoclas-
togenesis assays, peripheral blood mononuclear cells were used as a source for 
adherent cells and cultures were maintained for 21 d before TRAP staining. 
  Statistical analysis.     Readouts could not be assumed to be normally distrib-
uted as they were histological scores or percentages. Therefore, nonparamet-
ric Mann-Whitney  U   tests were used for statistical analysis. One-way unpaired 
and two-way ANOVAs were used when testing the infl  uence of third pa-
rameters such as time or dose. Analyses were performed on GraphPad Prizm 
v4. P-values of   ≤  0.05 were considered signifi  cant and values of   ≤  0.01 were 
considered highly signifi  cant. 
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